Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis

Fig. 2

PPARα agonists altered the metabolites of AA in TC-1 tumour-bearing mice. a Heat map of 25 changed eicosanoids (derived from AA) in tumours (n = 8–11). * # &P < 0.05, AVE, Wy, Beza vs control, respectively. B and c Levels of EETs and DHETs in tumours of PPARα agonist-treated mice (n = 8–11). * # &P < 0.05, AVE, Wy, Beza vs control, respectively; %P < 0.05, Beza vs Wy. d Levels of 11-HETE in tumours of PPARα agonist-treated mice (n = 8–11).* # &P < 0.05, AVE, Wy, Beza vs control. e and f Histograms showing eicosanoids profiles from lungs and livers of PPARα agonist-treated tumour-bearing mice (n = 8–11). * # &P < 0.05 AVE, Wy, Beza vs control. g Correlation between EET concentration and tumour volume

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us